Key result
The RAVENTA trial is a planned multi-center feasibility study designed to evaluate the 30-day safety of single-session 25 Gy cardiac radiosurgery in 20 patients with refractory ventricular tachycardia.
Why the study?
Cardiac radiosurgery has shown VT burden reductions in initial single-center studies, but its full safety profile remains largely unknown.
Does high-precision single-session radiosurgery with 25 Gy safely reduce ventricular tachycardia burden in patients with refractory ventricular tachycardia?
Does high-precision single-session radiosurgery with 25 Gy safely reduce ventricular tachycardia burden in patients with refractory ventricular tachycardia?
The RAVENTA trial is a planned multi-center feasibility study designed to evaluate the safety and initial efficacy of single-session 25 Gy cardiac radiosurgery for patients with refractory ventricular tachycardia.
Should not yet change refractory VT practice; hypothesis-generating for radiosurgery efficacy in larger trials.
BACKGROUND: Single-session high-dose stereotactic radiotherapy (radiosurgery) is a new treatment option for otherwise untreatable patients suffering from refractory ventricular tachycardia (VT). In the initial single-center case studies and feasibility trials, cardiac radiosurgery has led to significant reductions of VT burden with limited toxicities. However, the full safety profile remains largely unknown. METHODS/DESIGN: In this multi-center, multi-platform clinical feasibility trial which we plan is to assess the initial safety profile of radiosurgery for ventricular tachycardia (RAVENTA). High-precision image-guided single-session radiosurgery with 25 Gy will be delivered to the VT substrate determined by high-definition endocardial electrophysiological mapping. The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery. Secondary endpoints are the assessment of VT burden, reduction of implantable cardioverter defibrillator (ICD) interventions [shock, anti-tachycardia pacing (ATP)], mid-term side effects and quality-of-life (QoL) in the first year after radiosurgery. The planned sample size is 20 patients with the goal of demonstrating safety and feasibility of cardiac radiosurgery in ≥ 70% of the patients. Quality assurance is provided by initial contouring and planning benchmark studies, joint multi-center treatment decisions, sequential patient safety evaluations, interim analyses, independent monitoring, and a dedicated data and safety monitoring board. DISCUSSION: RAVENTA will be the first study to provide the initial robust multi-center multi-platform prospective data on the therapeutic value of cardiac radiosurgery for ventricular tachycardia. TRIAL REGISTRATION NUMBER: NCT03867747 (clinicaltrials.gov). Registered March 8, 2019. The study was initiated on November 18th, 2019, and is currently recruiting patients.
No takes yet. Share an insight, caveat, or question.
Blanck et al. (2020) studied Refractory ventricular tachycardia (n=20). Single-session high-dose stereotactic radiotherapy (radiosurgery) was evaluated on Safety (successful dose delivery without severe treatment-related side effects in the first 30 days after radiosurgery). The RAVENTA trial is a planned multi-center feasibility study designed to evaluate the 30-day safety of single-session 25 Gy cardiac radiosurgery in 20 patients with refractory ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: